Pliant Therapeutics (STU:9PT) FCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9PT Pliant Therapeutics Inc STU:9PT
35 GF Score
Price €0.94
GF Value €0.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics FCF Margin %?

Pliant Therapeutics STU:9PT -6.73% 35 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:9PT with a GF Score™ of 35/100 and a GF Value™ of €0.38 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Pliant Therapeutics ranks worse than 105263.05% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pliant Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €-16.63 Mil. Pliant Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Pliant Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Pliant Therapeutics's current FCF Yield % is -148.73%.

The historical rank and industry rank for Pliant Therapeutics's FCF Margin % or its related term are showing as below:


During the past 8 years, the highest FCF Margin % of Pliant Therapeutics was -6.51%. The lowest was -7422.91%. And the median was -995.26%.

STU:9PT's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28
* Ranked among companies with meaningful FCF Margin % only.

Pliant Therapeutics FCF Margin % Related Terms

Pliant Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Pliant Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pliant Therapeutics FCF Margin % Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -1,022.16 -995.22 -7,422.22 0.00 0.00

Pliant Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:9PT vs BYSI, MCRB, XBIT: FCF Margin % Comparison

For the Biotechnology subindustry, Pliant Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pliant Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's FCF Margin % falls into.


STU:9PT
35GF Score
Pliant Therapeutics Inc STU:9PT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pliant Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pliant Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-109.918/0
= %

Pliant Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-16.633/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Pliant Therapeutics (STU:9PT) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pliant Therapeutics and its competitors. According to the industry distribution chart, Pliant Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is Pliant Therapeutics' FCF Margin % too high?
Pliant Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Pliant Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pliant Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' FCF Margin % compare to BYSI and MCRB?
According to the Biotechnology industry distribution chart, Pliant Therapeutics ranks #999999 out of 950 companies for FCF Margin %. This places Pliant Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pliant Therapeutics and its competitors. Pliant Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Pliant Therapeutics (STU:9PT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.38, compared to a current price of €0.94 — trading 146.2% above its estimated fair value. The current FCF Margin % is 0.00%. Pliant Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pliant Therapeutics (STU:9PT), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pliant Therapeutics (STU:9PT) Overvalued in 2026?

Based on GuruFocus' analysis, Pliant Therapeutics stock appears to be overvalued. The current stock price of €0.94 is trading 146.2% above its estimated GF Value™ of €0.38. GuruFocus considers Pliant Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:9PT:

  • FCF Margin %: 0.00%
  • GF Value™: €0.38 vs. price of €0.94 (146.2% above fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the STU:9PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pliant Therapeutics Business Description

Other Exchanges PLRX:USA
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
35GF Score

Get the complete analysis for STU:9PT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.94
Price
€0.38
GF Value